University of Edinburgh spinout Kynos Therapeutics acquired by Dr. Falk Pharma
Natalia Elliot | October 30, 2024 | News story | Research and Development | Edinburgh, Internal Medicine, Microbiology, acquisitions, biopharma, inhibitors
Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase (KMO) inhibitors – has been acquired by Dr. Falk Pharma.
Dr. Falk Pharma focuses on developing treatments for a wide range of gastrointestinal disorders, and hopes to use Kynos Therapeutics’ KMO inhibitors to help treat acute and chronic inflammatory diseases. The primary indication being investigated is for acute pancreatitis, furthering Dr. Falk Pharma’s interest in rare metabolic diseases.
Co-founders Professor Damian Mole and Professor Scott Webster spun Kynos Therapeutics out of the University of Edinburgh, UK, with Jonathan Savidge acting as CEO since 2022. It received founding investment from Epidarex Capital, with further investment coming from IP Group and Scottish Enterprise. Its lead molecule, KNS366, performed well in a phase 1 trial, being found safe and well-tolerated.
“Kynos molecules are in excellent hands for the next steps of clinical development. I would like to thank all Kynos’ stakeholders for their support in completing this deal,” commented former CEO Jonathan Savidge.
Elizabeth Roper, general partner at Epidarex and former investor director of Kynos Therapeutics, added: “The acquisition by Dr. Falk Pharma of Kynos is an outstanding achievement by the company and provides a great example of Epidarex’s approach to company creation and development. We would like to congratulate the Kynos team and our fellow investors on the transaction with Dr. Falk Pharma. Targeting KMO represents a potentially transformative approach in acute pancreatitis.”
Charlie Blackie-Kelly
30/10/24
Related Content
Symeres announces acquisition of DGr Pharma
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug …
Bayer buys BlueRock Therapeutics for $600 million
Bayer has entered into an agreement to fully acquire engineered cell therapy firm BlueRock Therapeutics …
Contract manufacturing services industry set to grow at CAGR of 10.6% between 2017-2027
The biopharmaceutical contract manufacturing market is expected to grow at a compound annual growth rate …
